|Ian Gould (UK)
|Gianpaolo Perletti (Italy)
|Minggui Wang (China)
How to Join
Members of an ISC Member Society are eligible to join any of our Working Groups. If you are a member and would like to join this group, please contact the Chairperson and Secretary (if applicable).
Aims and Objectives
Antibiotic resistance is recognised worldwide as a major problem in the management of infectious disease, both in hospital settings and the community. While most major pharmaceutical companies have either abandoned or reduced efforts in antibiotic research and development in favour of areas such as chronic illness, smaller companies face many challenges but continue to pursue a wide variety of approaches.
The pharmaceutical industry, academic and government researchers are calling for new and increased collaborations among all stakeholders to strengthen the research and drug development processes. Improved information and active networks are linking resources and knowledge.
We are providing an international platform for promoting and encouraging the effective exchange of information about research and development activities in the anti-infective field. Our platform supports information flows between academia, clinicians and industry researchers and raises awareness on all sides for the needs of the medical community as well as the problems related to developing these drugs.
Academia: obtaining information about activities in their field of interest in other countries and settings, facilitate collaboration with industry
Clinicians: debating the need for and obtaining information about potential availability of future anti-infective and cancer drugs
Industry: sharing information and collaboration opportunities and research activities in their field, gaining visibility
7-10 May 2011
|Symposium at the 21st ECCMID/27th ICC in Milan, Italy with the ESCMID PK/PD of Anti-Infectives Study Group (EPASG) and the ISC Working Group: Antimicrobials of the Future
|6-9 June 2013
||Symposium at the 28th ICC in Yokohama, Japan: “New Antibiotics – Hope or Reality?”
Projects / Publications
Associate Partner in the project DRIVE-AB (Driving Reinvestment in R&D and Responsible Antibiotic Use). DRIVE-AB is a public-private consortium funded by the EU Innovative Medicines Initiative (IMI) and part of the New Drugs for Bad Bugs (ND4BB) programme. Drive Website
||Accelerating resistance, inadequate antibacterial pipelines and international responses. Int J Antimicr Agents 2012;39:295-9.
||Global antibacterial resistance: The never-ending story. J Global Antimicrob Resistance 2013, 1(2):63-69
Last updated: April 27th-2015